LIfT Biosciences – Summary

LIfT Biosciences’ aim is clear: to develop a cure for pancreatic cancer by 2021.

As a socially-minded Biotech start-up, they have been developing the world’s first cell bank of cancer killing granulocytes (a type of white blood cell).

The Cell Bank will provide a range of potentially life-saving immune-oncology cell therapies for different solid tumour types.

LIfT get their name from our innate immunity platform, known as Leukocyte Infusion Therapy.

LIfT was set-up with Prof Zhen Cui of Wake Forest University, a leading pioneer in LIfT, following his discovery of a mouse that was cancer resistant. He found that this had transferable innate immunity – meaning they could transfer this immunity.

The first target for LIfT is pancreatic cancer (pancreatic ductal adenocarcinoma – PDAC), one of the types of cancer with the highest unmet medical need.

CRUK report that just 3% of Patients Diagnosed with PDAC survive 5 years. PDAC is classified as an orphan disease by European Medicines Agency (EMA).

In addition, LIfT Biosciences is applying for LIfT to be classified as an Advanced Therapy Medicinal Product (ATMP), in particular as a Somatic Cell Therapy Medicinal product which will provide accelerated approval (early access scheme) and enhanced proprietary protection (market and data exclusivity).

They are currently completing pre-clinical work before running their first in-human clinical trial. The aim is to demonstrate by 2021 that LIfT is curative for Pancreatic Cancer.


CEO Alex Blyth comes from an entrepreneurial background, with 15 years’ experience in commercialising biopharma assets and strategy consulting.

He has advised teams and led the strategic planning on the launch of over 50 assets. Blyth founded the company after sadly losing his mother to Pancreatic Cancer.

Chief Medical and Scientific Officer Dr Nico Bruyniks has had an impressive career working as a gynaecologist and pharmaceutical physician, with 26 years’ experience in the pharmaceutical/biotech industry.

During this time, he worked in clinical and pre-clinical development, medical affairs and general management, as well as being EU Director for Clinical and Scientific affairs at Takeda and as Managing Director for Takeda Nordics.

As prementioned, Professor Zheng Cui is a key part of the LIfT Biosciences dynamic, working as Chief Clinical Advisor.

As well as his discovery of the ‘super mouse’, he has been working hard to develop the original Leukocyte Infusion Therapy technique.

Cui is committed to working with LIfT BioSciences to bring his ground-breaking work to patients.

Become a member – follow the lead of experienced investors. Sign Up